Somatostatin and somatostatin analogues in medullary thyroid carcinoma

Autor: Cullen Mj, O'Byrne Kj, Freyne Pj, Sweeney E, N J O'Hare
Rok vydání: 1996
Předmět:
Zdroj: Nuclear Medicine Communications. 17:810-816
ISSN: 0143-3636
DOI: 10.1097/00006231-199609000-00013
Popis: Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour characterized by the production and secretion of calcitonin. MTC tumours may express functional somatostatin receptors (hSSTR). A significant proportion of hSSTR receptor-positive MTC tumours, including metastatic disease, may be visualized in vivo through 111 In-pentetreotide scintigraphy. Four patients with recurrent/metastatic disease, who had previously been assessed with 111 In-anti-CEA monoclonal antibody fragment [F(ab') 2 ] imaging, were evaluated. 111 In-pentetreotide scintigraphy localized all known disease sites. Furthermore, mediastinal disease was detected in one patient with negative conventional and 111 In-anti-CEA F(ab') 2 imaging studies. The detection of somatostatin within the tumour (2 patients), or negative octreotide challenges (2 patients), did not affect the outcome of 111 In-pentetreotide scintigraphy. In conclusion, 111 In-pentetreotide scintigraphy appears at least as effective as 111 In-anti-CEA F(ab') 2 imaging and should be considered in the diagnostic evaluation of MTC, particularly in the setting of recurrent/metastatic disease not detected by conventional means.
Databáze: OpenAIRE